NR1I2 and hepatocellular carcinoma: Studies show that tanshinone IIA can enhance sorafenib metabolism in hepatocellular carcinoma via PXR activation (43–45), highlighting the PXR-microbiota axis’s role in reversing chemoresistance (Figure 1A).